Loading data for XCUR — first visit, this takes a few seconds.
Exicure, Inc. (XCUR)
NasdaqCM: XCUR
· Real-Time Price · USD
1.25
-0.01 (-0.79%)
At close: Sep 09, 2026, 8:00 PM
1.41
-1.40%
After-hours: 6:54 PM
The price, the headline numbers and the latest news, in one place.
Exicure, Inc. (XCUR) Stock Price, Analysis & Data
No data available
| Bid | 1.78 |
| Market Cap | 9.36M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.28M |
| 3.62 | |
| -1.31 | |
| n/a | |
| -1.86 | |
| P/B (ttm) | 4.35 |
| P/S (ttm) | 0.00 |
| Earnings Date | n/a |
| Ask | 1.71 |
| Volume | 16,544 |
| Avg. Volume (20D) | 413,177 |
| Open | 1.23 |
| Previous Close | 1.26 |
| Day's Range | 1.23 - 1.28 |
| 52-Week Range | 1.05 - 9.48 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About XCUR
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California....
Industry Biotechnology
Sector Healthcare
IPO Date May 22, 2018
Employees 1
Stock Exchange NasdaqCM
Ticker Symbol XCUR
Website https://www.exicuretx.com
Financial Performance
In 2025, Exicure's revenue was 0, a decrease of -100% compared to the previous year's 500K. Earnings were -4.95M, a decrease of -49.02%.
Financial StatementsEarnings Surprise
Exicure has released their quarterly earnings on Aug 15, 2022:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -8.3 misses estimates by -2.30, with 65.42% YoY growth.